Better Buy: GlaxoSmithKline vs. Eli Lilly
GlaxoSmithKline (NYSE: GSK) and Eli Lilly (NYSE: LLY) are enormous and profitable capstones of the pharmaceutical industry, responsible for discovering and commercializing dozens of new drugs each year. Both companies are backed by enormous drug development pipelines, some of the most capable leadership teams in the industry, and decades of highly successful competition within their markets.
For bargain-hunting investors, there's a lot to consider when it comes to which stock will make a better addition to their portfolios, especially considering how differently the two stocks have performed recently.
Image source: Getty Images.
Source Fool.com
